23: COVID-19 And Cardiovascular Disease
“We are at war with a pandemic and the enemy is not each other, it’s the virus.”
In this latest episode, Ankur Kalra, MD meets with Andrew Sauer, MD, co-author of upcoming paper in US Cardiology Review on COVID-19 and Cardiovascular Disease that provides a concise and current summary of cardiovascular complications from COVID-19.
Hear them discuss the latest issues surrounding the pandemic, the known cardiac implications and the rapidly emerging data.
Submit your question to Ankur via: podcast@radciffe-group.com. Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Read MoreRead Less
“It’s a tsunami not just a wave. The worst tsunami you can imagine”
Prof Michele Senni is Director of Cardiology at Papa Giovanni XXIII Hospital, Bergamo Italy. He contracted COVID-19 himself and in this latest podcast he meets with Ankur Kalra, MD to discuss his personal experience in dealing with patients and COVID-19 in Europe’s outbreak epicentre.
Hear them discuss the burden on healthcare, patient selection, the importance of testing and PPE and how COVID has resulted in a reduction of acute myocardial infarction and heart failure in patients.
Read More
Prof Michele Senni is Director of Cardiology at Papa Giovanni XXIII Hospital, Bergamo Italy. He contracted COVID-19 himself and in this latest podcast he meets with Ankur Kalra, MD to discuss his personal experience in dealing with patients and COVID-19 in Europe’s outbreak epicentre.
Hear them discuss the burden on healthcare, patient selection, the importance of testing and PPE and how COVID has resulted in a reduction of acute myocardial infarction and heart failure in patients.
All Episodes
EP 61: The Year 2021 in Review with Dr Sukh Nijjer — Top Trials in Heart Failure and Cardiac Surgery
In the second part of Parallax’s review of 2021, Dr Sukh Nijjer, Interventional Cardiologist from Imperial College London, and Dr Ankur Kalra discuss key advances in the field of heart failure and cardiac surgery.
Read More
In the last Parallax episode of the year, Dr Ankur Kalra welcomed back Dr Sukh Nijjer, Interventional Cardiologist from Imperial College London, to review the most impactful events and advances in cardiology from 2021.
Read More
In this AHA 2021 episode of Parallax, Dr Ankur Kalra’s guest is Dr Amit Khera, Professor and Director of Preventive Cardiology at UT Southwestern Medical Center, Dallas and Vice Chair of the Scientific Sessions. For this week’s show, Dr Khera selected three thought-provoking late-breaking trials that will inform or change clinical practice.
Read More
In this TCT 2021 episode of Parallax, Dr Ankur Kalra’s guest is Prof Mamas Mamas, Consultant Interventional Cardiologist at University Hospitals of North Midlands NHS Trust (UHNM), Professor of Cardiology at Keele University and Senior Clinical Editor of TCTmd.
Read More
In celebration of Diwali, Dr. Ankur Kalra sat down with Dr. Ambarish Pandey, Assistant Professor at The University of Texas Southwestern Medical School, to talk about his career path and the questions that shaped his decision-making over the years.
Read More
This week’s Parallax in collaboration with the Heart Failure Society of America (HFSA) explores the many ways organisations can embrace the needs of a diverse community and create a culture that can react to the realities of patientcare.
Read More
In the second ESC 2021 episode of Parallax, Dr Ankur Kalra’s guest is Dr. Mirvat Alasnag, interventional Cardiologist and Director of Catheterization Laboratory at the King Fahad Armed Forces Hospital (KFAFH) in Saudi Arabia. Dr Alasnag was a programme committee member at this year’s ESC and regional PI of one of the late-breaking trials presented.
Read More
In this special ESC 2021 edition of Parallax, Ankur asks Purvi to review the highlights of the congress. Purvi summarises the design and findings of the trials and their importance in the treatment of patients. Ankur and Purvi discuss how the novel data presented at ESC will inform their practice.
Read More
Dr Ankur Kalra’s guest is Dr Nasrien Ezzeldin Ibrahim, Director of Heart Failure Clinical Research at Inova Heart and Vascular Institute and the writer of SPARKPLUG: The Roadmap to Confidently Ignite and Navigate Your Career Without Compromising Your Dreams.
In this candid episode of Parallax, Nasrien and Ankur open up about their experiences of being an immigrant. Ankur asks Nasrien about her journey to medicine. Nasrien shares the lessons she took away from her years under the mentorship of Dr JoAnn Lindenfeld and later, Dr. James Januzzi. Finally, Nasrien shares her recent experience of writing Sparkplug and how she embraced life with its imperfections and found her purpose.
Read More
In this candid episode of Parallax, Nasrien and Ankur open up about their experiences of being an immigrant. Ankur asks Nasrien about her journey to medicine. Nasrien shares the lessons she took away from her years under the mentorship of Dr JoAnn Lindenfeld and later, Dr. James Januzzi. Finally, Nasrien shares her recent experience of writing Sparkplug and how she embraced life with its imperfections and found her purpose.
This week’s episode starts a series in collaboration with the Heart Failure Society of America (HFSA). Host, Ankur Kalra’s guests are Robert Mentz and Anuradha Lala Senior Editorial Team of the Journal of Cardiac Failure (JCF), the official journal of the HFSA and the Japanese Heart Failure Society (JHFS).
In this practical and insightful episode, Dr Kalra asks what does diversity, equity, inclusion and belonging mean to the editorial board of JCF and what were the steps taken to put these principles into practice.
Read More
In this practical and insightful episode, Dr Kalra asks what does diversity, equity, inclusion and belonging mean to the editorial board of JCF and what were the steps taken to put these principles into practice.
In celebration of this month’s ‘National Eat Your Vegetables Day’, this week’s guest is @TheVeggieMD, one of the most prominent physicians on social media! Dr Danielle Belardo MD is a Cardiology Fellow, American Board of Internal Medicine certified and a member of the American College of Cardiology Nutrition and Lifestyle Sub-Committee.
In this episode, Ankur and Danielle speak about the evidence in favour of a whole-food plant-based diet to improve cardiovascular health, the ACC prevention guidelines, how to talk to patients about positive dietary change, the issue of lack of nutrition training in cardiovascular fellowships and what Danielle’s diet looks like as a busy whole-food plant-based cardiology fellow. On her own podcast ‘Nutrition Rounds’ Danielle has discussions about evidence-based plant-based nutrition with physicians who are leading experts in nutrition and health.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
In this episode, Ankur and Danielle speak about the evidence in favour of a whole-food plant-based diet to improve cardiovascular health, the ACC prevention guidelines, how to talk to patients about positive dietary change, the issue of lack of nutrition training in cardiovascular fellowships and what Danielle’s diet looks like as a busy whole-food plant-based cardiology fellow. On her own podcast ‘Nutrition Rounds’ Danielle has discussions about evidence-based plant-based nutrition with physicians who are leading experts in nutrition and health.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Listen to our first episode with two guests! Ankur spoke with Emmanouil S Brilakis, MD and Michael Megaly, MD from the Minneapolis Heart Institute, Abbott Northwestern Hospital about their article on the role of drug-coated balloons in small-vessel coronary artery disease (SVD) published in US Cardiology Review 13.1. Percutaneous coronary intervention of SVD remains challenging due to difficulties with device delivery and high restenosis rate, making drug-coated balloons an attractive emerging option in patients with SVD.
In this brilliant conversation, Ankur, Emmanouil and Michael unravel the potential advantages, challenges and practical realities of using drug-coated balloons in SVD, and the findings of the latest randomised controlled trials studying this area.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology. [Disclaimer: The use of drug-coated balloons in coronay intervention is still off-label; it has not been approved by the FDA.]
Read More
In this brilliant conversation, Ankur, Emmanouil and Michael unravel the potential advantages, challenges and practical realities of using drug-coated balloons in SVD, and the findings of the latest randomised controlled trials studying this area.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology. [Disclaimer: The use of drug-coated balloons in coronay intervention is still off-label; it has not been approved by the FDA.]
We have observed a lot of developments in percutaneous coronary intervention (PCI) over the past 12 months with the publication of various studies and trials. This week, Ankur spoke with J. Dawn Abbott, MD, Associate Professor of Cardiology at Warren Medical School of Brown University about her recently published US Cardiology Review 13.1 article on the significant developments in PCI over the past 12 months.
Dawn is an associate editor of the journal Circulation: Cardiovascular Interventions and is widely known for her research program on PCI and peripheral arterial disease (PAD). Ankur and J. Dawn discuss multiple trials/studies that were published in 2018, including ORBITA, PIONEER-II and ABSORB. J. Dawn also shares her thoughts on the latest stent technologies.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
Dawn is an associate editor of the journal Circulation: Cardiovascular Interventions and is widely known for her research program on PCI and peripheral arterial disease (PAD). Ankur and J. Dawn discuss multiple trials/studies that were published in 2018, including ORBITA, PIONEER-II and ABSORB. J. Dawn also shares her thoughts on the latest stent technologies.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
This week’s podcast guest needs no introduction! Prof Athena Poppas is one of the most widely known cardiologists in the US and current Vice-President of the American College of Cardiology! Ankur spoke to Athena about her recently published US Cardiology Review 13.1 article on whether early management of hypertension by GPs can improve outcomes.
They discuss the importance of preventative medicine, their experience of reducing hypertension with non-pharmaceutical and pharmaceutical methods, and the significance of the integrated “team approach” when treating comorbid conditions such as hypertension. Athena also shares her thoughts on cardiologists’ responsibility to shape their patients’ lifestyle choices.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
They discuss the importance of preventative medicine, their experience of reducing hypertension with non-pharmaceutical and pharmaceutical methods, and the significance of the integrated “team approach” when treating comorbid conditions such as hypertension. Athena also shares her thoughts on cardiologists’ responsibility to shape their patients’ lifestyle choices.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Ankur is back with his second #AudioArticle! This week he spoke with Santiago Garcia from the Minneapolis Heart Institute about Santiago’s US Cardiology Review 13.1 article on the role of high-sensitivity cardiac troponin (hscTn) assays and their ability to rapidly rule in or rule out acute coronary syndrome (ACS) with improved sensitivity.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.